Recent studies investigating the mechanisms engaged by the host to terminate ongoing inflammation uncovered a new genus of molecules, produced by leukocytes that reprogram both stromal and leukocyte responses. [5] [6] [7] [8] [9] [10] Objective: Herein, we investigated the diurnal regulation of specialized proresolving mediators in humans and their role in controlling peripheral blood leukocyte and platelet activation.
G aining an understanding of the basic mechanisms that regulate physiological responses to environmental changes is of interest because they may shed light into the etiopathology of disease. 1 One basic environmental change that the body responds to is the light/dark cycle, which leads to a circadian regulation of many physiological functions, including leukocyte and platelet responses. 2, 3 Disturbances to various aspects of these fundamental mechanisms are thought to be responsible for many of the diseases that afflict modern societies, including cardiovascular and metabolic disorders. [2] [3] [4] These conditions are characterized by a dysregulated inflammatory response, although the exact mechanisms promoting this inflammatory state remain of interest.
termed as specialized proresolving mediators (SPMs), are produced via the enzymatic conversion of essential fatty acids, including n-3 docosapentaenoic acid (DPA), and are classified into 4 families: the lipoxins, resolvins, protectins, and maresins. 8 SPMs actively counter-regulate the production of proinflammatory mediators, including cytokines and eicosanoids, and regulate leukocyte trafficking and phenotype after both sterile and infectious challenge. [5] [6] [7] [8] [9] [10] [11] Furthermore, plasma SPM concentrations were recently found to reflect outcome in sepsis, 12 and increases plasma SPM concentrations in females are associated with improved endothelial function after challenge when compared with males. 13 Thus, peripheral blood SPM concentrations may provide insights into both physiological and pathological processes ongoing in the vasculature.
Given the potent vascular actions of SPM and the link between altered diurnal responses and several inflammatory conditions, including myocardial infarct, 14, 15 we investigated whether systemic SPM levels were diurnally regulated. We also assessed whether the temporal regulation of SPM was associated with changes in leukocyte and platelet responses.
Methods
Detailed Methods are given in the Online Data Supplement. The authors declare that all supporting data are available within the article and its online supplementary files.
Results

Diurnal Changes in Peripheral Blood n-3 DPADerived SPM Are Regulated by Acetylcholine in Healthy Volunteers
To investigate whether peripheral blood SPM concentrations are diurnally regulated, we obtained plasma from healthy volunteers at distinct intervals during a 24-hour period (Online Table I ). Here, we identified mediators from all 4 major essential fatty acid metabolomes (Online Figure I ). Multivariate analysis of plasma lipid mediator (LM) profiles demonstrated a diurnal shift in plasma LM concentrations with a leftward shift in LM clusters from morning to evening profiles ( Figure 1A and 1B). This shift was associated with an increase in the amounts of n-3 DPA-derived mediators, including RvD1 n-3 DPA and RvD5 n-3 DPA from the evening (18:00 hours) to morning intervals (7:00 and 9:00 hours; Figure 1C ; Online Table II) . Of note, diurnal changes in plasma RvD n-3 DPA concentrations were abrogated in mice lacking the main orchestrator of the molecular clock, BMAL1 (Aryl hydrocarbon receptor nuclear translocator-like protein 1), in myeloid cells (Online Figure  IG) . These diurnal changes in RvD n-3 DPA were associated with a regulation of leukocyte and platelet activation that reached a maximum between 7:00 and 9:00 hours coincident with an increase in RvD n-3 DPA concentrations (Figure 1D through 1F; Online Figure IIA) . We also found a significant association between peripheral blood RvD n-3 DPA concentrations and morning leukocyte activation, where lower RvD n-3 DPA were associated with increased peripheral blood leukocyte and platelet activation ( Investigations into mechanism(s) regulating peripheral blood n-3 DPA-derived SPM demonstrated that plasma acetylcholine (ACh) concentrations mirrored those of RvD n-3 DPA reaching a maximum at 7:00 hours (Online Figure IIIA) , suggesting that ACh may regulate the RvD n-3 DPA in peripheral blood given its role in SPM biosynthesis. 16 Incubation of What New Information Does This Article Contribute?
• Circulating concentrations of RvD n-3 DPA are regulated in a diurnal manner in healthy humans.
• RvD n-3 DPA regulate platelet-leukocyte activation, indicating that their increases in healthy volunteers is part of a physiological, protective counter-regulatory mechanism.
• In patients with cardiovascular disease, a decrease in RvD n-3 DPA was associated with increased plasma adenosine concentrations and platelet-leukocyte activation.
Many biological processes, including blood platelet and leukocyte activation, are regulated in a diurnal manner in healthy people.
In patients with cardiovascular disease, this diurnal activation of peripheral blood platelets and leukocytes is associated with an increased incidence of thrombus formation and infarct in the early morning hours. The mechanisms that counter-regulate this diurnal peripheral blood cell activation remain of interest. Herein, we found that RvD n-3 DPA , a novel family of protective mediators produced by white blood cells, are upregulated during peak peripheral blood cell activation in healthy volunteers and decrease platelet and leukocyte activation. Of note, in patients with cardiovascular disease, the production and diurnal regulation of these molecules were lost. This was associated with augmented platelet and white blood cell activation, and plasma adenoisne concentrations. Taken together, the present findings suggest that in healthy people maintaining the concentrations of these molecules in blood will help protect against blood vessel disease. Furthermore, in patients with blood vessel disease, strategies aiming at restoring the blood RvD n-3 DPA concentrations may be a useful approach to reducing blood vessel inflammation.
whole blood with ACh increased RvD n-3 DPA concentrations, including RvD2 n-3 DPA , under both static and flow conditions (Online Figure IIIB through IIIE; Table III) , an increase that was not linked with a selective mobilization of n-3 DPA by ACh (Online Table IV ). Of note, incubation of peripheral blood with norepinephrine 17 (n=6 donors; 0.1-10 µmol/L) or cortisol 18 (Online Table V ; 1-10 µmol/L), which are both diurnally regulated in the circulation, did not significantly Figure 1 . Vascular n-3 docosapentaenoic acid (DPA)-derived specialized proresolving mediators (SPMs) are diurnally regulated in human healthy volunteers. Peripheral blood was collected from healthy volunteers at the indicated intervals, and lipid mediator (LM) concentrations were determined using LM-profiling. A, Partial least squares discriminant analysis 2-dimensional (2D) score plot of the distinct LM-SPM profiles identified human plasma at the indicated intervals and (B) corresponding 2D loading plot. Grey ellipse in the score plots denotes 95% confidence regions. Grey and blue circles represent LM with a variable in importance score ≥1; n=4 healthy volunteers per interval. C, n-3 DPA-derived SPM concentrations identified and quantified at each of the time intervals. Results are mean±SEM, n=7 per time point and expressed as pg/mL. *P≤0.05 vs amounts at the 18-h interval using Wilcoxon signed-rank test. D, Neutrophil CD11b expression. E and F, Monocyte, (E) CD11b and (F) CD41 expression. Results are mean±SEM, n=7 volunteers per interval and expressed as percentage of 18:00 hours antigen expression. *P<0.05 vs 18:00 h interval, determined using Wilcoxon signed-rank test. Results in the grey panel are replotted from the white portion to aid in visualization of rhythmicity. G and H, Correlation between changes in monocyte (G) CD11b and (H) CD62P (9:00-18:00 h) expression and 9:00 RvD n-3 DPA concentrations. Results are representative of n=8 volunteers. Dashed line represents 95% CI. augment the production of n-3 DPA-derived mediators in peripheral blood from healthy volunteers. In line with these findings, administration of a glucocorticoid receptor antagonist (mifepristone) or an antagonist to β 1 -, β 2 -, and α 1 -adrenoceptors (carvedilol) to mice reduced diurnal increases in platelet-leukocyte interactions without significantly altering plasma RvD n-3 DPA (Online Figure IVA and  IVB) . Intriguingly, incubation of human peripheral blood with anti-PSGL1 (P-selectin glycoprotein ligand-1) antibody before the addition of either PAF (platelet-activating factor) or FMLP (N-formylmethionine-leucyl-phenylalanine) decreased both platelet-leukocyte aggregates and RvD n-3 DPA concentrations (Online Figure IVC) . These findings suggest that RvD n-3 DPA production is regulated by ACh in peripheral blood and that platelet-leukocyte heterotypic aggregates contribute to RvD n-3 DPA production in a stimulus-dependent manner.
RvD n-3 DPA Reduce Leukocyte and Platelet Activation in Peripheral Blood
We next investigated the actions of RvD n-3 DPA in regulating monocyte, neutrophil, and platelet activation, as well as platelet-leukocyte aggregates. Incubation of human peripheral blood with RvD2 n-3 DPA led to dose-dependent decreases in neutrophil CD11b expression and in neutrophil-platelet aggregates, measured as decreases in neutrophil CD62P (Figure 2A and 2B) and CD41 expression (n=5 donors; ≈20% decrease at 10 nmol/L) when compared with cells incubated with PAF alone. In these incubations, we also found a significant reduction in monocyte activation where RvD2 n-3 DPA gave dose-dependent decreases in monocyte expression of CD11b and in the platelet markers CD62P ( Figure 2C and 2D) and CD41 (n=5 donors; ≈29% decreased at 10 nmol/L). Similar findings were also made when healthy volunteer whole blood was incubated with RvD5 n-3 DPA that resulted in dose-dependent decreases in neutrophil and monocyte CD11b expression, as well as in leukocyte-platelet aggregates (Figure 2) . To obtain insights into the regulation of platelet-leukocyte interactions by RvD n-3 DPA , we used ImageStream and found that RvD5 n-3 DPA reduced both the number of leukocytes that carried platelets (ie, CD41 positive cells) and the number of platelets tethered to each leukocyte, measured as function of the number of pixels positive for CD41 staining per cell ( Figure 2E through 2G) .
We next investigated whether RvD n-3 DPA displayed direct antiplatelet actions. Incubation of RvD5 n-3 DPA with PRP (platelet-rich plasma) led to a dose-dependent reduction in PAF-mediated upregulation of CD62P, CD63, and CD41 expression ( Figure 2H ).
Reduced RvD n-3 DPA Concentrations Correlate With Increased Peripheral Blood Cell Activation in Patients With Cardiovascular Disease
Given the role that systemic platelet and leukocyte activation plays in cardiovascular disease (CVD), we next assessed RvD n-3 DPA concentrations in patients with CVD. Using LMprofiling, we found significant decreases in plasma RvD n-3 DPA concentrations and a marked impairment in their diurnal regulation in CVD patients when compared with healthy volunteers ( Figure 3A ; Online Table VII) .
Flow cytometric analysis of peripheral blood leukocyte from patients with CVD demonstrated increases in the expression of CD11b on both neutrophils and monocytes from CVD patients when compared with healthy volunteers (Figure 3B through 3E) . This was coupled with increases in platelet-neutrophil and platelet-monocyte aggregates in peripheral blood from patients with CVD ( Figure 3B  through 3E ). In addition, we found a significant relationship between peripheral blood RvD n-3 DPA concentration and leukocyte and platelet activation as demonstrated by a negative correlation between RvD n-3 DPA and neutrophil CD41, monocyte CD41, and platelet CD63 and CD42b expression ( Figure 3F through 3J) .
To establish the mechanisms leading to the downregulation of RvD n-3 DPA biosynthesis, we next assessed the expression of the RvD n-3 DPA biosynthetic enzymes in peripheral blood leukocytes. Flow cytometric assessment of peripheral blood myeloid cells from healthy volunteers and patients with CVD demonstrated a dysregulation in diurnal expression of SPM biosynthetic enzymes in CVD leukocytes (Figure VA through VC). These findings suggest that an impaired expression of these enzymes may contribute to altered RvD n-3 DPA biosynthesis.
Elevated Plasma Adenosine Reduces RvD n-3 DPA Biosynthesis in Patients With CVD
Given that we found a significant reduction in 7-HDPA concentrations in peripheral blood from patients with CVD (Online Figure VIA) , we investigated whether adenosine, which is known to regulate 5-LOX activity, 19 was elevated in plasma from these patients. LC/MS-MS analysis demonstrated an increase in the peripheral blood adenosine levels at all intervals tested when compared with healthy volunteers ( Figure 4A ). Incubation of peripheral blood from CVD patients with ADA (adenosine deaminase), the enzyme that degrades adenosine, 20 led to an increase in plasma RvD n-3 DPA concentrations ( Figure 4B ). We also found significant increases in plasma ACh levels and decreased 15-LOX expression in peripheral blood leukocytes in patients with CVD (Online Figures V and VI) . Of note, 17-HDPA concentrations, a marker of 15-LOX activity, 5 remained unchanged (Online Figure VIB) , suggesting that increases in ACh compensated for the decreased enzyme expression.
Reduced Leukocyte Activation by RvD2 n-3 DPA and RvD5 n-3 DPA in Patient Peripheral Blood
To test whether there was a relationship between the increased systemic inflammation and reduced n-3 DPA-derived SPM, we next investigated whether RvD n-3 DPA regulated patient peripheral blood leukocyte responses. RvD2 n-3 DPA and RvD5 n-3 DPA dosedependently decreased platelet-neutrophil and platelet-monocyte aggregates, as well as leukocyte and platelet activation ( Figure 4C through 4E) . These leukocyte and platelet directed actions were also retained when peripheral blood was incubated with PAF (Online Figure VII) . Thus, these findings suggest that reductions in circulating RvD n-3 DPA lead to increased peripheral blood leukocyte and platelet activation in patients with CVD.
RvD5 n-3 DPA Reduces Systemic Leukocyte and Platelet Activation and Protects Against Vascular Disease in ApoE −/− (Apolipoprotein E Deficient) Mice
We next investigated whether the leukocyte-directed actions of RvD5 n-3 DPA were also retained in vivo. In ApoE −/− mice fed Western diet for 6 weeks, RvD5 n-3 DPA administration reduced circulating platelet-leukocyte aggregates and activation ( Figure VIIIA and VIIIB). Liqid chromatography tandem mass spectrometric analysis of aortic sections from mice given RvD5 n-3 DPA demonstrated distinct LM profiles when compared with mice given vehicle. Here, we found increases Table VIII ). In addition, Oil red-O staining demonstrated that RvD5 n-3 DPA administration reduced aortic lesions ( Figure VIIID) . Together, these findings demonstrate that the protective actions of RvD5 n-3 DPA are also retained in vivo leading to reduced vascular disease. Figure 3 . Systemic n-3 docosapentaenoic acid (DPA)-derived specialized proresolving mediators (SPMs) are reduced, and leukocyte activation is increased in patients with cardiovascular disease (CVD). Peripheral blood from patients diagnosed with CVD was collected at 16:00 to 18:00 hours (PM), 9:00 hours (AM), and 12:00 hours (midday), lipid mediator (LM) was identified and quantified using LM-profiling (Methods for details). A, Plasma RvD n-3 DPA concentrations. Results are mean±SEM and expressed as pg/mL. n=14 CVD patients for AM, PM; n=5 for midday group; and n=7 healthy volunteers (HV). *P≤0.05 and **P≤0.01 compared with respective HV group using Mann-Whitney test; #P≤0.05 vs PM values using Friedman test followed by Dunn multiple comparisons test. B through E, Whole blood was incubated with fluorescently labeled antibodies, and cell activation as well as leukocyte-platelet aggregates were assessed using flow cytometry. B and C, CD11b expression on (B) neutrophils and (C) monocytes. D and E, CD62P expression on (D) neutrophils and (E) monocytes. *P≤0.05, **P≤0.01 compared with HV determined using Wilcoxon signed-rank test. n=5 HV and 9 CVD patients. F through J, Correlation among percent changes (AM to PM) in (F) neutrophil CD41, (G through H) monocyte (G) CD11b and (H) CD41, and (I and J) platelet (I) CD63 and (J) CD42b expression and 9:00-hour RvD n-3 DPA concentrations. Results are representative of n=8 to 10 patients. Dashed line represents 95% CI.
Discussion
In the present studies, we uncovered a novel host protective mechanism centered on the diurnal regulation of systemic RvD n-3 DPA . Recent findings implicate the neuronal system in regulating tissue proresolving mediator biosynthesis via release of the neurotransmitter ACh, a mechanism that is central in maintaining tissue resolution tone. 16 Results from the present studies demonstrate that the vascular levels of this neurotransmitter in healthy volunteers are diurnally regulated and increase during the early morning hours (Online Figure III) . Incubation of peripheral blood from healthy volunteers with ACh increased RvD n-3 DPA , indicating that this neurotransmitter was also involved in controlling the production of RvD n-3 DPA in peripheral blood. We also found that the contribution of platelet-leukocyte aggregates in RvD n-3 DPA biosynthesis is stimulus dependent, whereby alteration of platelet-leukocyte aggregates using different strategies (Online Figure IV) did not always significantly regulate RvD n-3 DPA biosynthesis. These findings suggest that additional mechanisms are involved in regulating RvD n-3 DPA production during these cellular interactions. This is also in line with the distinct biological actions associated with these heterotypic cell aggregates in the onset and propagation of systemic inflammation, actions that are linked with the production of a distinct mediator repertoire. [21] [22] [23] [24] [25] Given the protective actions that RvD n-3 DPA exert in regulating peripheral blood cell responses (Figures 1 through 4) and tissue protection, 6 the marked reductions in plasma RvD n-3 DPA (≈3-fold lower) during the early morning hours indicate that alterations in RvD n-3 DPA production may contribute to CVD onset and propagation. Although we cannot completely rule out an influence of the medications taken by these patients in regulating RvD n-3 DPA , the following lines of evidence support a role for increased adenosine in the downregulation of this pathway in patients with CVD (1) the medications taken by these patients are not known to directly regulate either 15-LOX or 5-LOX, (2) 7-HDPA concentrations, the marker of 5-LOX activity, were significantly downregulated in peripheral blood from patients with CVD, (3) 17-HDPA and 13-HDPA concentrations, markers of 15-LOX and COX activity, were not different in the morning hours, highlighting a specific loss in 5-LOX activity in patients with CVD, (4) 5-LOX was significantly downregulated in human peripheral blood leukocytes, (5) adenosine, known regulator of 5-LOX activity, 19 was significantly increased in plasma from patients with CVD, and (6) incubation of patient peripheral blood with ADA significantly upregulated (≈2-fold) plasma RvD n-3 DPA concentrations. Thus, these results suggest that increases in circulating adenosine are responsible for altered peripheral blood levels of these SPM in patients with CVD. These findings are also in line with findings made with peripheral blood from healthy volunteers demonstrating that reducing adenosine concentration during coagulation upregulates SPM biosynthesis. 20 In summation, the present findings uncover a novel protective pathway centered on the diurnal regulation of vascular n-3 DPA-derived resolvins that is lost in patients with CVD. Thereby, strategies to restore peripheral blood RvD n-3 DPA , including n-3 DPA supplementation that was recently shown to increase plasma RvD5 n-3 DPA in healthy volunteers, 26 may be a useful therapeutic option. In addition, RvD n-3 DPA -based therapeutics may also provide new opportunities for fine-tuning the increased inflammatory status present in these patients, dampening systemic inflammation and reducing vascular disease.
